Joint Pain Forum – News you can use!
Celebrex Patents Upheld Vs. Teva Challenge
Mar 20, 2007
NEW YORK (Reuters)
Inc. said on Tuesday a U.S. court upheld the three main
patents covering its Celebrex arthritis treatment, winning a challenge
by generic drugmaker Teva Pharmaceutical Industries Ltd.
The decision by the U.S. District Court in Newark, New Jersey bars
Israel-based Teva from launching a competitor drug in the U.S. until
December 2015, Pfizer said.
Pfizer had filed suit against Teva in February
2004 after the generic drugmaker asked U.S. regulators for permission
to sell a copycat version of Celebrex.
which was approved in 1998 and had sales last year of $1.57 billion, is
in the same class of medicines as Merck & Co's
withdrawn Vioxx pain and arthritis treatment.
pill works by blocking a protein called COX-2 that is linked to
inflammation. Although designed to treat pain with a smaller risk of
gastrointestinal problems than far less-expensive conventional
painkillers, Celebrex has not proven such a safety advantage in
Map | CONTACT